BCTXBriaCell Therapeutics Corp.
Health Care
Share-based Payment Arrangement, Noncash Expense revised down 15.5% for FY 2025
This is the 5th largest revision in BCTX's history.
Share-based Payment Arrangement, Noncash Expense·FY 2025
Major restatement$656.8K▼ 15.5%
was$776.9K
Revised down in a 10-K.
Verify against SEC filingsShow
As reported$776.9K
Accepted 2025-10-160001493152-25-018212
Restated$656.8K
Accepted 2026-10-280001493152-26-049041
StockBasedCompensation · reported 2 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time BCTX — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.